130 related articles for article (PubMed ID: 37191945)
1. Risk analysis of subsequent therapies after first-line chemotherapy in advanced testicular cancer patients.
Yen TH; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Chen CP; Yang CR; Li JR
J Chin Med Assoc; 2023 Jul; 86(7):646-652. PubMed ID: 37191945
[TBL] [Abstract][Full Text] [Related]
2. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
4. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin containing combination chemotherapy of advanced germ cell line testicular tumours.
Bodrogi I; Baki M; Horti J; Géczi L; Liszka G; Ottó S; Hindy I; Eckhardt S; Sugár J
Acta Med Hung; 1994; 50(3-4):275-92. PubMed ID: 8587840
[TBL] [Abstract][Full Text] [Related]
6. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG).
Berger LA; Bokemeyer C; Lorch A; Hentrich M; Kopp HG; Gauler TC; Beyer J; de Wit M; Mayer F; Boehlke I; Oing C; Honecker F; Oechsle K
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1211-20. PubMed ID: 24696231
[TBL] [Abstract][Full Text] [Related]
7. Disease Characteristics and Treatment Outcome of Testicular Germ Cell Tumors Treated with Platinum-Based Regimens.
Sattar A; Masood M; Nisar H; Fatima I; Shahid AB
J Coll Physicians Surg Pak; 2018 Apr; 28(4):292-296. PubMed ID: 29615170
[TBL] [Abstract][Full Text] [Related]
8. Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy.
Miller RE; Markt SC; O'Donnell E; Bernard B; Albiges LK; Beard C; Sweeney CJ
Eur Urol Focus; 2017 Dec; 3(6):621-628. PubMed ID: 28753801
[TBL] [Abstract][Full Text] [Related]
9. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
10. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
11. [Result of treatment for advanced germ cell tumor in the last decade].
Ishioka J; Kageyama Y; Inoue M; Fukui N; Numao N; Saito K; Ichiyanagi N; Tanak M; Hyochi N; Fukuda H; Higashi Y
Nihon Hinyokika Gakkai Zasshi; 2010 Mar; 101(3):539-46. PubMed ID: 20387513
[TBL] [Abstract][Full Text] [Related]
12. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.
Rodenhuis S; de Wit R; de Mulder PH; Keizer HJ; Sleijfer DT; Lalisang RI; Bakker PJ; Mandjes I; Kooi M; de Vries EG
Ann Oncol; 1999 Dec; 10(12):1467-73. PubMed ID: 10643538
[TBL] [Abstract][Full Text] [Related]
13. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
14. Importance of continuous sequential chemotherapy and multimodal treatment for advanced testicular cancer: a high-volume Japanese center experience.
Nakamura T; Ueda T; Oishi M; Nakanishi H; Shiraishi T; Fujihara A; Naito Y; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Medicine (Baltimore); 2015 Mar; 94(11):e653. PubMed ID: 25789960
[TBL] [Abstract][Full Text] [Related]
15. Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.
Tryakin A; Fedyanin M; Bulanov A; Kashia S; Kurmukov I; Matveev V; Fainstein I; Gordeeva O; Zakharova T; Tjulandin S
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1817-1823. PubMed ID: 29974210
[TBL] [Abstract][Full Text] [Related]
16. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
[TBL] [Abstract][Full Text] [Related]
17. Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.
Kundu SD; Feldman DR; Carver BS; Gupta A; Bosl GJ; Motzer RJ; Bajorin DF; Sheinfeld J
J Urol; 2015 Feb; 193(2):513-8. PubMed ID: 25150639
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
19. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
20. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
